Fundraising Fox

Aeovian Pharmaceuticals

Berkeley, US · Founded 2012 · Delaware corporation · 6 known investors

aeovian.com ↗

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.

Biotech

Founders & leadership

AJ
Allison J. HulmeCEO & President
JK
John KincaidChief Scientific Officer
YB
Youssef BennaniDirector
TK
Themasap KhanDirector
NR
Nils ReggeDirector
DR
Davis RymanExecutive Officer
WG
William GreeneDirector
MZ
Micah ZajicExecutive Officer
LE
Lars EkmanDirector
JG
Justin GoverDirector
IM
Ian MasseyExecutive Officer
ST
Stelios TzannisExecutive Officer, Director

Investors · 6

CoastCapVienna
CTI Life Sciences Fund L.P.Montréal
FJ LabsNew York · $250K – $2M
Sofinnova VenturesMenlo Park · $100K – $15Mvia Lars Ekman · board
venBio PartnersSan Franciscovia Richard Gaster · board
venBio Global StrategicreportedSan Francisco

Reported raises · per SEC filings

Form D private placements
▶$55MraisedDec 2025 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • John KincaidExecutive Officer
  • Youssef BennaniDirector
  • Themasap KhanDirector
  • Nils ReggeDirector
  • Davis RymanExecutive Officer
  • William GreeneDirector
  • Micah ZajicExecutive Officer
  • Lars EkmanDirector
  • Justin GoverDirector
  • Allison J. HulmeExecutive Officer, Director
  • Richard GasterDirector
Offering amount
$55M
Amount sold
$55M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50.4MraisedMay 2024 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Davis C. RymanExecutive Officer
  • Nils ReggeDirector
  • Matthew J. PlunkettExecutive Officer
  • William GreeneDirector
  • Allison J. HulmeExecutive Officer, Director
  • John F. KincaidExecutive Officer
  • Richard GasterDirector
  • Lars EkmDirector
Offering amount
$50.4M
Amount sold
$50.4M
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18.8MraisedOct 2019 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stelios TzannisExecutive Officer, Director
  • Jens EcksteinDirector
  • Ben ZadikExecutive Officer
  • Michael PowellDirector
  • Richard GasterDirector
Offering amount
$48.8M
Amount sold
$18.8M
First sale
Sep 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$785.7KraisedJun 2017 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ian MasseyExecutive Officer
  • Stelios TzannisExecutive Officer, Director
  • Ben ZadikExecutive Officer
  • David LoweDirector
  • James PeyerDirector
Offering amount
$3.8M
Amount sold
$785.7K
First sale
Jun 2017
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news